Coadministered Cagrilintide and Semaglutide for Obesity

Created using ChatSlide

This NEJM-published Phase 3a multicenter trial investigated the combined weight-loss efficacy of Cagrilintide-Semaglutide in 3417 adults with BMI ≥30 or associated complications over 68 weeks. Primary endpoints included percent body weight change, with secondary measures assessing metabolic improvements like glucose and lipid profiles. Results demonstrated significant weight reduction of -20.4%, with over half achieving ≥20% weight loss. Safety profiles revealed mild to moderate...